Lymphocyte depleting and modulating therapies for chronic lung allograft dysfunction
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F23%3A10464979" target="_blank" >RIV/00064203:_____/23:10464979 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11130/23:10464979
Result on the web
<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=9uLrW8WCOc" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=9uLrW8WCOc</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1124/pharmrev.123.000834" target="_blank" >10.1124/pharmrev.123.000834</a>
Alternative languages
Result language
angličtina
Original language name
Lymphocyte depleting and modulating therapies for chronic lung allograft dysfunction
Original language description
Chronic lung rejection, also called chronic lung allograft dysfunction (CLAD), remains the major hurdle limiting long-term survival after lung transplantation and limited therapeutic options are available to slow the progressive decline in lung function. Most interventions are only temporarily effective in stabilising the loss of or modestly improving lung function, with disease progression resuming over time in the majority of patients. Therefore, identification of effective treatments that prevent the onset or halt progression of CLAD is urgently needed. As a key effector cell in its pathophysiology, lymphocytes have been considered a therapeutic target in CLAD. The aim of this review is to evaluate the use and efficacy of lymphocyte depleting and immunomodulating therapies in progressive CLAD beyond usual maintenance immunosuppressive strategies. Modalities used include anti-thymocyte globulin, alemtuzumab, methotrexate, cyclophosphamide, total lymphoid irradiation and extracorporeal photopheresis, and to explore possible future strategies. When considering both efficacy and risk of side effects, extracorporeal photopheresis, anti-thymocyte globulin and total lymphoid irradiation appear to offer the best treatment options currently available for progressive CLAD patients. Significance Statement Effective treatments to prevent the onset and progression of chronic lung rejection after lung transplantation are still a major shortcoming. Based on existing data to date, considering both efficacy and risk of side effects, extracorporeal photopheresis, anti-thymocyte globulin and total lymphoid irradiation are currently the most viable second-line treatment options. Although important to note that interpretation of most results is hampered by the lack of randomised controlled trials.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30203 - Respiratory systems
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Pharmacological Reviews
ISSN
0031-6997
e-ISSN
1521-0081
Volume of the periodical
75
Issue of the periodical within the volume
6
Country of publishing house
US - UNITED STATES
Number of pages
18
Pages from-to
1200-1217
UT code for WoS article
001098885600005
EID of the result in the Scopus database
2-s2.0-85174752191